Mounjaro® and vomiting

Who vomited, in which trials

The US label’s main adult figures come from SURPASS-1 and SURPASS-5, placebo-controlled diabetes trials in which 718 adults took tirzepatide for an average of 36.6 weeks ^[1]. The pediatric trial, SURPASS-PEDS, gave 5 mg or 10 mg to 97 children and teenagers with type 2 diabetes, with a 30-week placebo-controlled period. SURPASS-CVOT followed 6,647 adults with diabetes and heart disease on doses up to 15 mg for a median of 210.1 weeks, against dulaglutide rather than placebo; 12% of them reported vomiting, and the label gives no figure for the dulaglutide group ^[1].

Canada’s monograph prints the placebo pool unrounded and adds a pool of seven phase 3 trials with 5,119 people on tirzepatide ^[4]. Each figure counts people who vomited at least once in the trial period, not how often they vomited.

How the European information grades it

The European Medicines Agency places vomiting in different frequency bands depending on who was treated. It is “very common”, meaning at least 1 person in 10, in the weight-management, SURPASS-CVOT, sleep apnoea, heart failure and pediatric diabetes trials, and “common”, meaning up to 1 in 10, in adult diabetes trials ^[3]. That is a useful reminder that the US diabetes table may understate what people using tirzepatide for weight see. The European patient leaflet adds that vomiting in adults treated for diabetes usually decreases over time ^[3].

Trial reviews point the same way. Across SURPASS-1 to -5, vomiting was reported by 2% to 13% of people on tirzepatide, depending on trial and dose ^[6]. A meta-analysis of tirzepatide in type 2 diabetes found that, compared with placebo, the 15 mg dose had odds of vomiting about 5.5 times higher, though the confidence interval was wide ^[5]. No label gives a separate stopping rate for vomiting; stomach and bowel reactions together led 3.0% to 6.6% of adults on Mounjaro® to stop in the US placebo pool, against 0.4% on placebo ^[1].

Why children stand out

Sections 6.1 and 8.4 of the US label say reactions in children aged 10 and older matched those in adults, except that vomiting, stomach pain and low blood sugar were more frequent ^[1]. The European information reports the same three exceptions ^[3]. Neither document offers a reason.

Two practical details frame the pediatric numbers. The highest dose for children is 10 mg a week, not 15 mg, and the US label does not recommend the multi-dose KwikPen for self-injection by children; a caregiver gives those injections ^[1][2]. Any decision about a child’s treatment rests with the prescribing clinician.

Why tirzepatide can bring on vomiting

What the labels support: tirzepatide delays stomach emptying, most strongly after the first dose, and the US label says most nausea, vomiting and diarrhea reports came during dose escalation and eased afterwards ^[1]. The step-up schedule of at least four weeks per dose is there to lower the risk of these reactions ^[1].

What has been reported beyond the trial tables: Canada’s monograph notes reports of events related to impaired stomach emptying, including severe gastroparesis, and asks clinicians to monitor people with severe stomach symptoms and consider changing the dose or stopping ^[4]. A review of GLP-1 medicines and tirzepatide found that food is left in the stomach more often in people taking them, although this rarely led to inhaling stomach contents during procedures ^[7].

General background: MedlinePlus lists slow stomach emptying among the common causes of nausea and vomiting, alongside infections, food poisoning and reflux ^[8].

When vomiting points to something else

Vomiting can come from a stomach virus, food poisoning, migraine, pregnancy, motion sickness or severe pain, and more seriously from appendicitis, a blocked bowel or an ulcer ^[8]. The tirzepatide labels name several specific possibilities. Acute pancreatitis causes severe, lasting stomach pain that may reach the back, with or without vomiting ^[1][2]. Gallbladder problems bring upper stomach pain, fever, yellowing or clay-coloured stools ^[2].

After approval, ileus and intestinal obstruction have been reported with Mounjaro® ^[1]. Canada’s patient information describes ileus as being unable to tolerate food, with bloating, stomach pain and severe nausea and vomiting, and gastroparesis as pain with severe nausea and vomiting, prolonged belching and prolonged bloating ^[4]. Taking too much is another cause: the European leaflet says an overdose can lower blood sugar and make you feel or be sick ^[3].

Fluids, kidneys and blood sugar

The US label reports acute kidney injury after approval, sometimes needing dialysis, most often where fluid lost through nausea, vomiting or diarrhea had left people dehydrated, and asks for kidney checks in such patients, especially early on and after dose increases ^[1]. The European information adds that the risk of dehydration and electrolyte problems deserves particular attention in older people ^[3].

MedlinePlus lists the early signs of dehydration as thirst, a dry or sticky mouth, passing little urine, darker urine, headache and muscle cramps, and the signs of severe dehydration as very dark or no urine, confusion, dizziness, a racing heart and fast breathing ^[9]. For mild dehydration it suggests sipping water, sucking ice cubes or drinking fluids with electrolytes, and warns against salt tablets ^[9].

If you also use insulin or a sulfonylurea, vomiting raises another issue. Mounjaro® on top of these medicines already increases the risk of low blood sugar, and the NIH notes that skipping or delaying meals, or not taking in enough carbohydrates, can push blood glucose too low ^[1][10]. Your diabetes team can tell you how to handle sick days.

Vomiting before a procedure

Rare cases of inhaled stomach contents have been reported in people on GLP-1 medicines who had general anaesthesia or deep sedation, even when they followed fasting instructions ^[1]. The US label says the evidence is too thin to know whether longer fasting or pausing Mounjaro® would help, and asks patients to tell every healthcare provider about the medicine before any planned procedure ^[1][2]. If you have been vomiting in the days before a procedure, mention that as well.

What to tell your prescriber

Useful details: how many times you vomited and over how many hours, whether you could keep fluids down, how much you passed urine, when your last injection and last dose change were, and whether pain, fever or diarrhea came with it. The European leaflet asks you not to change your dose unless your doctor has told you to, and the US Medication Guide asks you to use the medicine exactly as prescribed ^[2][3].

Mounjaro® and KwikPen® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.